The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Study Drug Riociguat (Adempas, BAY63-2521)
Type of Study Drug CFTR Modulation
Study Title Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta ∆F508 Homozygous Cystic Fibrosis Patients.
Study Phase 2
Study Sponsor Bayer

Link on (link is external)

Participating ECFS-CTN sites Germany: Berlin
UK: Belfast, London
Age 18 Years and older